MIRA Pharmaceuticals, Inc. Common Stock - Asset Resilience Ratio
MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has an Asset Resilience Ratio of 64.12% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MIRA net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how MIRA Pharmaceuticals, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MIRA Pharmaceuticals, Inc. Common Stock (MIRA) total assets.
Liquid Assets Composition Over Time
This chart breaks down MIRA Pharmaceuticals, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read MIRA Pharmaceuticals, Inc. Common Stock (MIRA) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.89 Million | 64.12% |
| Total Liquid Assets | $4.89 Million | 64.12% |
Asset Resilience Insights
- Very High Liquidity: MIRA Pharmaceuticals, Inc. Common Stock maintains exceptional liquid asset reserves at 64.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MIRA Pharmaceuticals, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare MIRA Pharmaceuticals, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.06% |
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 0.00% |
Annual Asset Resilience Ratio for MIRA Pharmaceuticals, Inc. Common Stock (None–None)
The table below shows the annual Asset Resilience Ratio data for MIRA Pharmaceuticals, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling tr… Read more